| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IMA |
| Uniprot No | O15131 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-539aa |
| 氨基酸序列 | MDAMASPGKDNYRMKSYKNKALNPQEMRRRREEEGIQLRKQKREEQLFKRRNVYLPRNDESMLESPIQDPDISSTVPIPEEEVVTTDMVQMIFSNNADQQLTATQKFRKLLSKEPNPPIDQVIQKPGVVQRFVKFLERNENCTLQFEAAWALTNIASGTFLHTKVVIETGAVPIFIKLLNSEHEDVQEQAVWALGNIAGDNAECRDFVLNCEILPPLLELLTNSNRLTTTRNAVWALSNLCRGKNPPPNFSKVSPCLNVLSRLLFSSDPDVLADVCWALSYLSDGPNDKIQAVIDSGVCRRLVELLMHNDYKVVSPALRAVGNIVTGDDIQTQVILNCSALPCLLHLLSSPKESIRKEACWTVSNITAGNRAQIQAVIDANIFPVLIEILQKAEFRTRKEAAWAITNATSGGTPEQIRYLVALGCIKPLCDLLTVMDSKIVQVALNGLENILRLGEQESKQNGIGINPYCALIEEAYGLDKIEFLQSHENQEIYQKAFDLIEHYFGVEEDDPSIVPQVDENQQQFIFQQQEAPMDGFQL |
| 预测分子量 | 60 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IMA重组蛋白的虚构参考文献示例，供参考格式和内容方向：
---
1. **文献名称**：*"High-Yield Production of IMA-Recombinant Protein in Pichia pastoris: Optimization and Functional Analysis"*
**作者**：Chen L. et al.
**摘要**：研究利用毕赤酵母系统高效表达IMA重组蛋白，通过优化启动子及培养条件提升产量，并验证其在体外免疫检测中的生物活性。
2. **文献名称**：*"IMA-Recombinant Protein Conjugated Nanoparticles for Enhanced Drug Delivery in Neurodegenerative Diseases"*
**作者**：Gupta R. et al.
**摘要**：开发了一种结合IMA重组蛋白的纳米颗粒载体，可穿越血脑屏障，显著提高阿尔茨海默病模型小鼠中的药物递送效率。
3. **文献名称**：*"Crystallographic Insights into the Binding Mechanism of IMA-Recombinant Protein with Antigenic Targets"*
**作者**：Tanaka K. et al.
**摘要**：通过X射线晶体学解析了IMA重组蛋白与特定抗原的复合物结构，阐明其高亲和力结合的分子基础，为疫苗设计提供理论支持。
4. **文献名称**：*"Diagnostic Potential of IMA-Recombinant Protein in Early Detection of Bacterial Infections"*
**作者**：Müller S. et al.
**摘要**：评估IMA重组蛋白作为生物标志物探针的效能，临床研究表明其可快速识别败血症患者血清中的病原体特异性抗体。
---
**提示**：以上为示例文献，实际研究中请通过学术数据库(如PubMed、Web of Science)检索真实文献，并核对作者、标题及摘要准确性。
**Background of IMA Recombinant Proteins**
Recombinant proteins, such as those developed under the IMA (Immune Modulatory Agent) platform, are engineered using advanced biotechnology to mimic or enhance naturally occurring proteins. These proteins are produced by introducing specific DNA sequences into host organisms (e.g., bacteria, yeast, or mammalian cells), enabling large-scale synthesis of target proteins with high purity and consistency. The IMA platform focuses on designing proteins that modulate immune responses, offering potential therapeutic applications in autoimmune diseases, cancer, and infectious diseases.
The development of recombinant protein technology began in the 1970s with breakthroughs in genetic engineering, such as the creation of synthetic insulin. Over time, advancements in expression systems, protein folding, and purification methods (e.g., affinity chromatography) have optimized production efficiency. IMA-based proteins often incorporate features like enhanced stability, reduced immunogenicity, or targeted delivery, achieved through techniques like site-directed mutagenesis or fusion tags.
IMA recombinant proteins are particularly valuable in immunotherapy. For example, they may act as cytokine analogs to regulate inflammation, checkpoint inhibitors to boost anti-tumor immunity, or antigen-presenting molecules for vaccine development. Their scalability and customization make them preferable to traditional therapies, which often face limitations in specificity or manufacturing complexity.
Despite their promise, challenges remain, including ensuring proper post-translational modifications in non-mammalian systems and minimizing production costs. Ongoing research aims to refine expression platforms and improve functional characterization. As personalized medicine grows, IMA recombinant proteins are poised to play a pivotal role in next-generation biologics, bridging gaps in treating complex immune-related disorders.
×
